ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015
Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Prognostic value of decreased FOXP1 protein expression in various tumors: a systematic review and meta-analysis.Scientific reports · 2016Pooled it
- Identification of FOXP1 as a favorable prognostic biomarker and tumor suppressor in intrahepatic cholangiocarcinoma.BMC cancer · 2024Article
- miR-34a-FOXP1 Loop in Ovarian Cancer.ACS omega · 2023Article
- Identification of transcriptional programs using dense vector representations defined by mutual information with GeneVector.Nature communications · 2023Article
- Long noncoding RNAAging · 2020Article
- miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.Cell cycle (Georgetown, Tex.) · 2020Article
- Expression of FOXP1 and FOXO3a in extrahepatic cholangiocarcinoma and the implications in clinicopathological significance and prognosis.OncoTargets and therapy · 2019Article
- microRNA-605 inhibits the oncogenicity of non-small-cell lung cancer by directly targeting Forkhead Box P1.OncoTargets and therapy · 2019Article
- The Dominant Role of Forkhead Box Proteins in Cancer.International journal of molecular sciences · 2018Review
- Cytoplasmic FOXP1 expression is correlated with ER and calpain II expression and predicts a poor outcome in breast cancer.Diagnostic pathology · 2018Article
- MicroRNA-152 inhibits ovarian cancer cell proliferation and migration and may infer improved outcomes in ovarian cancer through targeting FOXP1.Experimental and therapeutic medicine · 2018Article
- Upregulation of FOXP1 is a new independent unfavorable prognosticator and a specific predictor of lymphatic dissemination in cutaneous melanoma patients.OncoTargets and therapy · 2018Article
- MiR-206 is down-regulated and suppresses cell proliferation by targeting FOXP1 in brain gliomas.International journal of clinical and experimental pathology · 2018Article
- Article
- Epstein-Barr virus encoded miR-BART11 promotes inflammation-induced carcinogenesis by targeting FOXP1.Oncotarget · 2016Article
- FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to investigate the expression of FOXP1 in ovarian tumors and correlate it with clinicopathological parameters, chemotherapy resistance, and prognosis. FOXP1 messenger RNA (mRNA) expression was examined in fresh ovarian cancer tissues and normal ovarian tissues, and FOXP1 protein expression was determined in a total of 201 ovarian tissue samples, including 152 cases of primary epithelial ovarian cancer, 26 borderline ovarian tumors, 13 benign ovarian tumors, and 10 normal ovarian tissues. Complete chemotherapy and follow-up data were available in 92 of the 152 epithelial ovarian cancer patients. The relationship between FOXP1 protein expression and ovarian cancer pathological characteristics, chemotherapy resistance, and survival time was analyzed. FOXP1 mRNA expression was downregulated in ovarian cancer tissues compared with that in normal ovarian tissues. Decreased nuclear and increased cytoplasmic FOXP1 protein expression was correlated with increasing tumor grade. Nuclear FOXP1 expression was an independent risk factor associated with chemotherapy resistance and the prognosis of patients with ovarian cancer. FOXP1 expression is closely related to the degree of malignancy of epithelial ovarian cancer and may be a reliable index of the chemoresistance and prognosis of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.